The global research antibodies market size was valued at USD 1.59 billion in 2023 and is expected to grow at compound annual growth rate (CAGR) of 4.76% from 2024 to 2030. B cells are responsible for producing antibodies, which are essential components of the human immune system. These molecules are ideal probes for studying cells since they can attach themselves to particular molecules and can be employed to separate or identify important chemicals found in cells. These attributes of antibodies are anticipated to drive their adoption in various research applications in the near future. The outbreak of COVID-19 has created lucrative opportunities in the research antibodies market. Several leading pharmaceutical companies are investing heavily in R&D to create brand-new vaccinations, treatments, and testing tools for this pandemic.
The need for research antibodies has greatly increased as a result of these intense R&D operations for the development of novel vaccination and therapy techniques. Additionally, a number of public and commercial entities are making significant efforts to fund the development of COVID-19 vaccines and therapeutics. For instance, in April 2020, Emergent BioSolutions, a biopharmaceutical company, received USD 14.5 million from the federal government to work on an antibody therapy study for COVID-19.
In addition, antibodies are currently one of the most crucial tools for research projects exploring the functions of various proteins in cells. The prevalence of neurodegenerative conditions including Huntington's disease, Multiple Sclerosis, and Parkinson's disease is fueling research prospects aimed at better understanding of such diseases. Furthermore, the increase in geriatric population and a dearth of remedies for chronic diseases have also contributed to a sharp increase in demand for research antibodies to create customized medicines, cutting-edge pharmaceuticals, and novel & effective treatments.
One of the key reasons fueling the growth of the market for research antibodies is the increase in demand for high-quality antibodies for reproducible research. The market is also witnessing growth due to the expanding landscape of proteomics and genomics research as well as increased research and development efforts in the life sciences domain. Furthermore, the market is also influenced by the rise of industry-academia partnerships as well as the expanding stem cell research and neurobiology research fields to provide for the unmet medical needs across the globe.
In addition, an increase in funding for research initiatives from for-profit and nonprofit groups, as well as rising focus on biomarker development and outsourcing interests is driving the market growth. Moreover, the growing demand for protein therapies and personalized medicine are opening new market opportunities and present lucrative growth prospects for the research antibodies market players over the forecast period. For instance, in 2021, Thermo Fisher acquired PPD, extending its value proposition for pharmaceutical and biotechnology clients with the addition of PPD's top clinical research services. Such endeavors by biotechnology corporations are anticipated to boost the market growth.
The market growth stage is low, and pace of the market growth is accelerating. The market is witnessing increasing investments in the development of novel research-use only (RUO) antibodies. Furthermore, with the rise in demand for innovative research-use only products for application areas such as flow cytometry, cell signaling, epigenetics, etc., research antibodies are expected to witness significant growth in near future.
Key innovations in the market are driving advancements in specificity, sensitivity, and multiplexing capabilities of research antibodies. Novel technologies are enhancing antibody performance and enable researchers to explore complex biological processes which is likely to contribute towards market growth.
Several key players are undertaking mergers and acquisitions in this industry to maintain their market presence. For instance, in December 2023, Danaher acquired Abcam for USD 5.7 billion to strengthen its product portfolio and increase customer reach. Such strategies are anticipated to drive the growth of research antibodies market over the forecast period.
Regulations in this market include guidelines for enhancing data reproducibility and trust in experimental outcomes. However, navigating complex regulatory landscapes can pose challenges for companies, impacting product development timelines and costs in research and development activities.
The market has moderate to high levels of product and regional expansion. Increasing availability of product offerings, such as primary and secondary antibodies, across various geographies is enhancing experimental flexibility and accuracy. This expansion is anticipated to propel scientific discoveries by providing researchers with a more comprehensive range of tools for varied applications.
The primary antibodies segment captured the highest revenue share of 74.46% in 2023, and is also projected to grow at the fastest rate throughout the forecast period. This can be attributed to increasing availability of primary antibodies using rabbit, mouse, goat, and other species as host, and the wide range of utility offered by such antibodies for applications in the R&D space. Also, owing to the usage of primary antibodies for frequently performed laboratory procedures, such as staining and imaging, the segment is predicted to grow at an exponential rate.
The secondary antibodies segment is expected to grow at a significant CAGR from 2024 to 2030 as these are more convenient and cost-effective to develop. Demand for secondary research antibodies is also anticipated to increase due to the availability of ready-to-use conjugated antibodies that can improve product development activities by assisting in the identification, grouping, and purification of targeted antigens. For instance, Thermo Fisher Scientific, Inc. provides fluorescent dye-conjugated secondary antibodies that make it easier to identify proteins in a variety of applications, including immunohistochemistry, western blotting, and fluorescent cell imaging, among others.
Monoclonal antibodies segment accounted for the dominant share of the market in 2023, due to a sharp increase in the number of cancer research projects that demand high specificity antibodies. As monoclonal antibodies can efficiently adhere to or block antigens on cancer cells, these are employed in the identification and development of new medicines for various cancer types. This factor is expected to expand the growth prospects for the segment in the near future.
Polyclonal antibodies are projected to grow at lucrative CAGR over the forecast period as these antibody structures are essential for the research aspects focusing on purification of antigens and examination of histopathological tissue. Furthermore, polyclonal antibodies provide benefits like stability, practical storage methods, strong affinity, and excellent compatibility for ELISA and western blotting technologies, thereby propelling the market growth.
Western blotting segment accounted for the largest market share in 2023, due to the widespread availability and adoption of the technique. In addition, due to the increased accuracy that the western blotting technique offers, it is typically chosen over alternative technologies for applications involving the detection of important protein entities. These attributes are expected to positively affect the segment growth.
Immunohistochemistry segment is projected to grow at the fastest CAGR from 2024 to 2030. The segment is anticipated to expand steadily due to its significant applications in detection of enzymes, antigens, tumor suppressor genes, and tumor cell growth for cell-based research. Additionally, rising R&D spending and a high level of scientific awareness regarding the technique have led to increasing growth prospects for immunohistochemistry. Furthermore, benefits provided by the technique, such as high sensitivity & simplicity of use, are some of the factors anticipated to drive the market growth.
The rabbit source segment held the largest market share in 2023. Rabbits are extensively used for antibody production, owing to several advantages such as higher affinity antibodies provided by rabbits as compared to those obtained from other animal hosts. Furthermore, higher specificity provided by these antibodies makes them ideal for detection of small molecules, hormones, toxins and other biologically important substances.
Mouse source segment is anticipated to witness the fastest CAGR from 2024 to 2030. Mice have been predominantly used in production of antibodies due their high reproduction rate and smaller size. Furthermore, the main factor influencing their widespread use is the structural similarity between mouse and human antibodies, which can significantly drive their adoption for R&D applications.
Oncology segment accounted for the largest market share in 2023, owing to rise in prevalence of cancer in key geographies. According to the American Cancer Society, in 2021, over 1.9 million new cancer cases were estimated to be recorded in the U.S. Additionally, over 608,570 cancer deaths were also recorded in the same year in the U.S. As a result, more research antibodies will likely be used for designing and evaluation of new diagnostic and therapeutic approaches for mitigation of cancer.
Stem cells segment is expected to witness the fastest CAGR from 2024 to 2030 owing to increase in number of stem cell research activities globally. The growth is also attributable to increase in adoption of stem cells for the treatment of a wide range of chronic ailments such as diabetes, cancer, Alzheimer’s, Parkinson’s, rheumatoid arthritis, and kidney and lung diseases. Furthermore, antibodies are also used for stem cell research areas that include disease modeling, developmental biology, drug screening, reprogramming techniques development, and cell therapy that can positively affect the market growth.
The academic & research institutions segment captured the highest revenue share in 2023 and is projected to grow at the fastest growth rate throughout the forecast period. This can be attributed to the increase in scientific initiatives by such centers for development of novel therapies and tests for chronic diseases. For instance, in January 2021, researchers at The University of Texas Medical Branch at Galveston (UTMB Health) and The University of Texas Health Science Center at Houston (UTHealth) discovered two novel antibodies CoV2-06 and CoV2-14 for a potential novel antibody therapy for COVID-19 infection. Such initiatives can positively affect the segment growth in the near future.
Pharmaceutical and biotechnology companies end-use segment is expected to grow at a significant CAGR over the forecast period due to the increase in R&D activities in life sciences domain. Furthermore, the increasing importance of antibodies for development of novel biologic products and rising demand for quality control applications for various techniques, such as PCR and electrophoresis, are likely to boost the segment growth.
North America dominated the market in 2023 by capturing the largest revenue share of 39.15%. Growing emphasis on biomedical, stem cells, as well as cancer research, is a major contributor to its large market share. Presence of key players such as Thermo Fisher Scientific, Inc. and PerkinElmer, Inc. among others and increasing number of biotechnology & biopharmaceutical firms in the region that focus on life sciences innovation are expected to drive the market growth.
The market in the Asia Pacific region is expected to grow at the fastest CAGR from 2024 to 2030 due to an increase in collaborative activities among academic institutions. For instance, scientists from Tsinghua University, China Medical University, and the Vaccine Research Center at the NIH are currently conducting a research study on the identification and characterization of HIV-1 strains as well as their robust and widespread resistance to a variety of neutralizing antibodies. The National Natural Science Foundation Award, China's Ministry of Science and Technology, and Gates Foundation Grand Challenges China all supported this project. As a result, such government-funded scientific activities in the region are anticipated to drive the market growth.
Key players in this market are undertaking various strategic initiatives such as mergers, acquisitions, and collaborations to strengthen their market position and enhance their offerings across various geographical region. Strategic activities related to new product launch are also prominent in this market.
In July 2023, Bio-Techne Corporation announced the completion of acquisition of Lunaphore. The intent of this business decision was to augment the companies’ spatial biology leadership in the fields of translational and clinical research.
In June 2023, Cell Signaling Technology (CST) announced its partnership with Lunaphore. This initiative was aimed at enabling the deployment of CST antibodies on the COMET platform by Lunaphore for strengthening fully-automated spatial biology.
In April 2023, Abcam teamed up with Lunaphore to co-commercialize primary antibodies from Abcam. These antibodies were precisely validated for use on the COMET platform by Lunaphore.
In February 2023, Cell Signaling Technology entered into a partnership with Bio-Techne. This deal was aimed at the inclusion of Bio-Techne’s Simple Western validation to CST antibodies.
In March 2022, Sysmex America, Inc., expanded its reagents portfolio for single-color antibodies, cell stains and buffering solutions and introduced several new products in this domain.
Report Attribute |
Details |
Market size value in 2024 |
USD 1.68 billion |
Revenue forecast in 2030 |
USD 2.21 billion |
Growth rate |
CAGR of 4.76% from 2024 to 2030 |
Actual data |
2018 - 2023 |
Forecast period |
2024 - 2030 |
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, type, technology, source, application, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; India; Japan; Australia; Thailand; South Korea; Singapore; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Abcam Plc; Merck KGaA; Thermo Fisher Scientific, Inc.; Cell Signalling Technology, Inc.; Santa Cruz Biotechnology Inc.; PerkinElmer, Inc.; Becton; Dickinson and Company; Bio-Techne Corporation; Proteintech Group, Inc.; Jackson ImmunoResearch Inc. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global research antibodies on the basis of product, type, technology, source, application, end-use, and region:
Product Outlook (Revenue, USD Billion, 2018 - 2030)
Primary Antibodies
Secondary Antibodies
Type Outlook (Revenue, USD Billion, 2018 - 2030)
Monoclonal Antibodies
Polyclonal Antibodies
Technology Outlook (Revenue, USD Billion, 2018 - 2030)
Immunohistochemistry
Immunofluorescence
Western Blotting
Flow Cytometry
Immunoprecipitation
ELISA
Others
Source Outlook (Revenue, USD Billion, 2018 - 2030)
Mouse
Rabbit
Goat
Others
Application Outlook (Revenue, USD Billion, 2018 - 2030)
Infectious Diseases
Immunology
Oncology
Stem Cells
Neurobiology
Others
End Use Outlook (Revenue, USD Billion, 2018 - 2030)
Academic & Research Institutes
Contract Research Organizations
Pharmaceutical & Biotechnology Companies
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Singapore
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. Primary antibodies dominated the research antibodies market with a share of 74.5% in 2022. This is attributable to high adoption due to benefits such as easy availability, greater specificity, and suitability to various research needs.
b. Some key players operating in the research antibodies market include PerkinElmer, Inc.; F.Hoffmann La Roche Ltd.; Thermo Fisher Scientific; Merck Millipore; Bio-Rad Laboratories; Abcam PLC; BD; Lonza Group; Cell Signalling Technology, Inc.; and Agilent Technologies.
b. Key factors that are driving the research antibodies market growth include a rise in the number of R&D activities by various biopharmaceutical and pharmaceutical companies and increasing incidence of neurodegenerative diseases such as Huntington’s disease, Multiple Sclerosis, and Parkinson’s disease.
b. The global research antibodies market size was estimated at USD 1.5 billion in 2022 and is expected to reach USD 1.59 billion in 2023.
b. The global research antibodies market is expected to grow at a compound annual growth rate of 4.76% from 2023 to 2030 to reach USD 2.21 billion by 2030.
Table of Contents
Chapter 1. Research Antibodies Market: Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product Segment
1.1.2. Type Segment
1.1.3. Technology Segment
1.1.4. Source Segment
1.1.5. Application Segment
1.1.6. End-use Segment
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List Of Secondary Sources
1.8. List Of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Research Antibodies Market: Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Research Antibodies Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Investment In R&D
3.2.1.2. Growing Stem Cells and Neurobiology Research
3.2.1.3. Increase In Research Academies and Industry Collaborations
3.2.1.4. Rise In the Availability of Technologically Advanced Products
3.2.1.5. Rise In Proteomics and Genomics Research
3.2.2. Market Restraint and Challenges Analysis
3.2.2.1. Uncertain Government Regulations
3.2.2.2. Quality Concerns Associated with Research Antibodies and Time- & Cost-Intensive Process Of Antibody Development
3.2.3. Market Opportunities Analysis
3.2.3.1. Growing Demand for Personalized Medicine and Rising Focus on Biomarker Discovery
3.2.3.2. Increasing Opportunities In Various Emerging Markets
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
3.4. Pricing Analysis
Chapter 4. Product Business Analysis
4.1. Research Antibodies Market: Product Movement Analysis
4.2. Primary Antibodies
4.2.1. Primary Antibodies Market, 2018 - 2030 (USD Billion)
4.3. Secondary Antibodies
4.3.1. Secondary Antibodies Market, 2018 - 2030 (USD Billion)
Chapter 5. Type Business Analysis
5.1. Research Antibodies Market: Type Movement Analysis
5.2. Monoclonal Antibodies
5.2.1. Monoclonal Antibodies Market, 2018 - 2030 (USD Billion)
5.3. Polyclonal Antibodies
5.3.1. Polyclonal Antibodies Market, 2018 - 2030 (USD Billion)
Chapter 6. Technology Business Analysis
6.1. Research Antibodies Market: Technology Movement Analysis
6.2. Immunohistochemistry
6.2.1. Immunohistochemistry Market, 2018 - 2030 (USD Billion)
6.3. Immunofluorescence
6.3.1. Immunofluorescence Market, 2018 - 2030 (USD Billion)
6.4. Western Blotting
6.4.1. Western Blotting Market, 2018 - 2030 (USD Billion)
6.5. Flow Cytometry
6.5.1. Flow Cytometry Market, 2018 - 2030 (USD Billion)
6.6. Immunoprecipitation
6.6.1. Immunoprecipitation Market, 2018 - 2030 (USD Billion)
6.7. ELISA
6.7.1. ELISA Market, 2018 - 2030 (USD Billion)
6.8. Others
6.8.1. Other Technologies Market, 2018 - 2030 (USD Billion)
Chapter 7. Source Business Analysis
7.1. Research Antibodies Market: Source Movement Analysis
7.2. Mouse
7.2.1. Mouse Market, 2018 - 2030 (USD Billion)
7.3. Rabbit
7.3.1. Rabbit Market, 2018 - 2030 (USD Billion)
7.4. Goat
7.4.1. Goat Market, 2018 - 2030 (USD Billion)
7.5. Others
7.5.1. Other Sources Market, 2018 - 2030 (USD Billion)
Chapter 8. Application Business Analysis
8.1. Research Antibodies Market: Application Movement Analysis
8.2. Infectious Diseases
8.2.1. Infectious Diseases Market, 2018 - 2030 (USD Billion)
8.3. Immunology
8.3.1. Immunology Market, 2018 - 2030 (USD Billion)
8.4. Oncology
8.4.1. Oncology Market, 2018 - 2030 (USD Billion)
8.5. Stem Cells
8.5.1. Stem Cells Market, 2018 - 2030 (USD Billion)
8.6. Neurobiology
8.6.1. Neurobiology Market, 2018 - 2030 (USD Billion)
8.7. Others
8.7.1. Other Applications Market, 2018 - 2030 (USD Billion)
Chapter 9. End-Use Business Analysis
9.1. Research Antibodies Market: End-use Movement Analysis
9.2. Academic & Research Institutes
9.2.1. Academic & Research Institutes Market, 2018 - 2030 (USD Billion)
9.3. Contract Research Organizations
9.3.1. Contract Research Organizations Market, 2018 - 2030 (USD Billion)
9.4. Pharmaceutical & Biotechnology Companies
9.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Billion)
Chapter 10. Regional Business Analysis
10.1. Research Antibodies Market Share By Region, 2023 & 2030
10.2. North America
10.2.1. SWOT Analysis
10.2.2. North America Research Antibodies Market, 2018 - 2030 (USD Billion)
10.2.3. U.S.
10.2.3.1. Key Country Dynamics
10.2.3.2. Target Disease Prevalence
10.2.3.3. Competitive Scenario
10.2.3.4. U.S. Research Antibodies Market, 2018 - 2030 (USD Billion)
10.2.4. Canada
10.2.4.1. Key Country Dynamics
10.2.4.2. Target Disease Prevalence
10.2.4.3. Competitive Scenario
10.2.4.4. Canada Research Antibodies Market, 2018 - 2030 (USD Billion)
10.3. Europe
10.3.1. SWOT Analysis
10.3.2. Europe Research Antibodies Market, 2018 - 2030 (USD Billion)
10.3.3. UK
10.3.3.1. Key Country Dynamics
10.3.3.2. Target Disease Prevalence
10.3.3.3. Competitive Scenario
10.3.3.4. UK Research Antibodies Market, 2018 - 2030 (USD Billion)
10.3.4. Germany
10.3.4.1. Key Country Dynamics
10.3.4.2. Target Disease Prevalence
10.3.4.3. Competitive Scenario
10.3.4.4. Germany Research Antibodies Market, 2018 - 2030 (USD Billion)
10.3.5. France
10.3.5.1. Key Country Dynamics
10.3.5.2. Target Disease Prevalence
10.3.5.3. Competitive Scenario
10.3.5.4. France Research Antibodies Market, 2018 - 2030 (USD Billion)
10.3.6. Italy
10.3.6.1. Key Country Dynamics
10.3.6.2. Target Disease Prevalence
10.3.6.3. Competitive Scenario
10.3.6.4. Italy Research Antibodies Market, 2018 - 2030 (USD Billion)
10.3.7. Spain
10.3.7.1. Key Country Dynamics
10.3.7.2. Target Disease Prevalence
10.3.7.3. Competitive Scenario
10.3.7.4. Spain Research Antibodies Market, 2018 - 2030 (USD Billion)
10.3.8. Denmark
10.3.8.1. Key Country Dynamics
10.3.8.2. Target Disease Prevalence
10.3.8.3. Competitive Scenario
10.3.8.4. Denmark Research Antibodies Market, 2018 - 2030 (USD Billion)
10.3.9. Sweden
10.3.9.1. Key Country Dynamics
10.3.9.2. Target Disease Prevalence
10.3.9.3. Competitive Scenario
10.3.9.4. Sweden Research Antibodies Market, 2018 - 2030 (USD Billion)
10.3.10. Norway
10.3.10.1. Key Country Dynamics
10.3.10.2. Target Disease Prevalence
10.3.10.3. Competitive Scenario
10.3.10.4. Norway Research Antibodies Market, 2018 - 2030 (USD Billion)
10.4. Asia Pacific
10.4.1. SWOT Analysis
10.4.2. Asia Pacific Research Antibodies Market, 2018 - 2030 (USD Billion)
10.4.3. Japan
10.4.3.1. Key Country Dynamics
10.4.3.2. Target Disease Prevalence
10.4.3.3. Competitive Scenario
10.4.3.4. Japan Research Antibodies Market, 2018 - 2030 (USD Billion)
10.4.4. China
10.4.4.1. Key Country Dynamics
10.4.4.2. Target Disease Prevalence
10.4.4.3. Competitive Scenario
10.4.4.4. China Research Antibodies Market, 2018 - 2030 (USD Billion)
10.4.5. India
10.4.5.1. Key Country Dynamics
10.4.5.2. Target Disease Prevalence
10.4.5.3. Competitive Scenario
10.4.5.4. India Research Antibodies Market, 2018 - 2030 (USD Billion)
10.4.6. Australia
10.4.6.1. Key Country Dynamics
10.4.6.2. Target Disease Prevalence
10.4.6.3. Competitive Scenario
10.4.6.4. Australia Research Antibodies Market, 2018 - 2030 (USD Billion)
10.4.7. Thailand
10.4.7.1. Key Country Dynamics
10.4.7.2. Target Disease Prevalence
10.4.7.3. Competitive Scenario
10.4.7.4. Thailand Research Antibodies Market, 2018 - 2030 (USD Billion)
10.4.8. South Korea
10.4.8.1. Key Country Dynamics
10.4.8.2. Target Disease Prevalence
10.4.8.3. Competitive Scenario
10.4.8.4. South Korea Research Antibodies Market, 2018 - 2030 (USD Billion)
10.4.9. Singapore
10.4.9.1. Key Country Dynamics
10.4.9.2. Target Disease Prevalence
10.4.9.3. Competitive Scenario
10.4.9.4. Singapore Research Antibodies Market, 2018 - 2030 (USD Billion)
10.5. Latin America
10.5.1. SWOT Analysis
10.5.2. Latin America Research Antibodies Market, 2018 - 2030 (USD Billion)
10.5.3. Brazil
10.5.3.1. Key Country Dynamics
10.5.3.2. Target Disease Prevalence
10.5.3.3. Competitive Scenario
10.5.3.4. Brazil Research Antibodies Market, 2018 - 2030 (USD Billion)
10.5.4. Mexico
10.5.4.1. Key Country Dynamics
10.5.4.2. Target Disease Prevalence
10.5.4.3. Competitive Scenario
10.5.4.4. Mexico Research Antibodies Market, 2018 - 2030 (USD Billion)
10.5.5. Argentina
10.5.5.1. Key Country Dynamics
10.5.5.2. Target Disease Prevalence
10.5.5.3. Competitive Scenario
10.5.5.4. Argentina Research Antibodies Market, 2018 - 2030 (USD Billion)
10.6. MEA
10.6.1. SWOT Analysis
10.6.2. MEA Research Antibodies Market, 2018 - 2030 (USD Billion)
10.6.3. South Africa
10.6.3.1. Key Country Dynamics
10.6.3.2. Target Disease Prevalence
10.6.3.3. Competitive Scenario
10.6.3.4. South Africa Research Antibodies Market, 2018 - 2030 (USD Billion)
10.6.4. Saudi Arabia
10.6.4.1. Key Country Dynamics
10.6.4.2. Target Disease Prevalence
10.6.4.3. Competitive Scenario
10.6.4.4. Saudi Arabia Research Antibodies Market, 2018 - 2030 (USD Billion)
10.6.5. UAE
10.6.5.1. Key Country Dynamics
10.6.5.2. Target Disease Prevalence
10.6.5.3. Competitive Scenario
10.6.5.4. UAE Research Antibodies Market, 2018 - 2030 (USD Billion)
10.6.6. Kuwait
10.6.6.1. Key Country Dynamics
10.6.6.2. Target Disease Prevalence
10.6.6.3. Competitive Scenario
10.6.6.4. Kuwait Research Antibodies Market, 2018 - 2030 (USD Billion)
Chapter 11. Competitive Landscape
11.1. Company Categorization
11.2. Strategy Mapping
11.3. Company Market Share Analysis, 2023
11.4. Company Profiles/Listing
11.4.1. Abcam Plc
11.4.1.1. Overview
11.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.1.3. Product Benchmarking
11.4.1.4. Strategic Initiatives
11.4.2. Merck KGaA
11.4.2.1. Overview
11.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.2.3. Product Benchmarking
11.4.2.4. Strategic Initiatives
11.4.3. Thermo Fisher Scientific, Inc.
11.4.3.1. Overview
11.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.3.3. Product Benchmarking
11.4.3.4. Strategic Initiatives
11.4.4. Cell Signaling Technology, Inc.
11.4.4.1. Overview
11.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.4.3. Product Benchmarking
11.4.4.4. Strategic Initiatives
11.4.5. Santa Cruz Biotechnology Inc.
11.4.5.1. Overview
11.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.5.3. Product Benchmarking
11.4.5.4. Strategic Initiatives
11.4.6. PerkinElmer, Inc.
11.4.6.1. Overview
11.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.6.3. Product Benchmarking
11.4.6.4. Strategic Initiatives
11.4.7. Becton, Dickinson and Company
11.4.7.1. Overview
11.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.7.3. Product Benchmarking
11.4.7.4. Strategic Initiatives
11.4.8. Bio-Techne Corporation
11.4.8.1. Overview
11.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.8.3. Product Benchmarking
11.4.8.4. Strategic Initiatives
11.4.9. Proteintech Group, Inc.
11.4.9.1. Overview
11.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.9.3. Product Benchmarking
11.4.9.4. Strategic Initiatives
11.4.10. Jackson ImmunoResearch Inc
11.4.10.1. Overview
11.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
11.4.10.3. Product Benchmarking
11.4.10.4. Strategic Initiative
List of Tables
Table 1 List of abbreviations
Table 2 Global research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 3 Global research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 4 Global research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 5 Global research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 6 Global research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 7 Global research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 8 Global research antibodies market, by region, 2018 - 2030 (USD Billion)
Table 9 North America research antibodies market, by country, 2018 - 2030 (USD Billion)
Table 10 North America research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 11 North America research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 12 North America research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 13 North America research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 14 North America research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 15 North America research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 16 U.S. research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 17 U.S. research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 18 U.S. research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 19 U.S. research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 20 U.S. research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 21 U.S. research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 22 Canada research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 23 Canada research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 24 Canada research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 25 Canada research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 26 Canada research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 27 Canada research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 28 Europe research antibodies market, by country, 2018 - 2030 (USD Billion)
Table 29 Europe research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 30 Europe research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 31 Europe research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 32 Europe research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 33 Europe research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 34 Europe research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 35 UK research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 36 UK research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 37 UK research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 38 UK research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 39 UK research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 40 UK research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 41 Germany research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 42 Germany research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 43 Germany research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 44 Germany research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 45 Germany research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 46 Germany research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 47 France research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 48 France research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 49 France research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 50 France research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 51 France research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 52 France research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 53 Italy research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 54 Italy research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 55 Italy research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 56 Italy research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 57 Italy research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 58 Italy research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 59 Spain research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 60 Spain research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 61 Spain research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 62 Spain research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 63 Spain research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 64 Spain research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 65 Denmark research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 66 Denmark research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 67 Denmark research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 68 Denmark research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 69 Denmark research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 70 Denmark research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 71 Sweden research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 72 Sweden research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 73 Sweden research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 74 Sweden research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 75 Sweden research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 76 Sweden research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 77 Norway research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 78 Norway research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 79 Norway research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 80 Norway research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 81 Norway research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 82 Norway research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 83 Asia Pacific research antibodies market, by country, 2018 - 2030 (USD Billion)
Table 84 Asia Pacific research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 85 Asia Pacific research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 86 Asia Pacific research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 87 Asia Pacific research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 88 Asia Pacific research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 89 Asia Pacific research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 90 Japan research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 91 Japan research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 92 Japan research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 93 Japan research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 94 Japan research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 95 Japan research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 96 China research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 97 China research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 98 China research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 99 China research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 100 China research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 101 China research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 102 India research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 103 India research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 104 India research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 105 India research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 106 India research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 107 India research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 108 South Korea research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 109 South Korea research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 110 South Korea research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 111 South Korea research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 112 South Korea research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 113 South Korea research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 114 Thailand research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 115 Thailand research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 116 Thailand research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 117 Thailand research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 118 Thailand research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 119 Thailand research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 120 Australia research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 121 Australia research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 122 Australia research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 123 Australia research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 124 Australia research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 125 Australia research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 126 Singapore research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 127 Singapore research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 128 Singapore research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 129 Singapore research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 130 Singapore research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 131 Singapore research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 132 Latin America research antibodies market, by country, 2018 - 2030 (USD Billion)
Table 133 Latin America research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 134 Latin America research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 135 Latin America research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 136 Latin America research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 137 Latin America research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 138 Latin America research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 139 Brazil research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 140 Brazil research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 141 Brazil research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 142 Brazil research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 143 Brazil research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 144 Brazil research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 145 Mexico research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 146 Mexico research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 147 Mexico research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 148 Mexico research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 149 Mexico research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 150 Mexico research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 151 Argentina research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 152 Argentina research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 153 Argentina research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 154 Argentina research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 155 Argentina research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 156 Argentina research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 157 MEA research antibodies market, by country, 2018 - 2030 (USD Billion)
Table 158 MEA research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 159 MEA research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 160 MEA research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 161 MEA research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 162 MEA research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 163 MEA research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 164 South Africa research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 165 South Africa research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 166 South Africa research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 167 South Africa research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 168 South Africa research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 169 South Africa research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 170 Saudi Arabia research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 171 Saudi Arabia research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 172 Saudi Arabia research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 173 Saudi Arabia research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 174 Saudi Arabia research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 175 Saudi Arabia research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 176 UAE research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 177 UAE research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 178 UAE research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 179 UAE research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 180 UAE research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 181 UAE research antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 182 Kuwait research antibodies market, by product, 2018 - 2030 (USD Billion)
Table 183 Kuwait research antibodies market, by type, 2018 - 2030 (USD Billion)
Table 184 Kuwait research antibodies market, by technology, 2018 - 2030 (USD Billion)
Table 185 Kuwait research antibodies market, by source, 2018 - 2030 (USD Billion)
Table 186 Kuwait research antibodies market, by application, 2018 - 2030 (USD Billion)
Table 187 Kuwait research antibodies market, by end-use, 2018 - 2030 (USD Billion)
List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain-based sizing & forecasting
Figure 6 Market formulation & validation
Figure 7 Research antibodies market segmentation
Figure 8 Market snapshot, 2023
Figure 9 Market trends & outlook
Figure 10 Market driver relevance analysis (current & future impact)
Figure 11 Market restraint relevance analysis (current & future impact)
Figure 12 PESTEL analysis
Figure 13 Porter’s five forces analysis
Figure 14 Global research antibodies market: Product movement analysis
Figure 15 Global research antibodies market, for primary antibodies, 2018 - 2030 (USD Billion)
Figure 16 Global research antibodies market, for secondary antibodies, 2018 - 2030 (USD Billion)
Figure 17 Global research antibodies market: Type movement analysis
Figure 18 Global research antibodies market, for monoclonal antibodies, 2018 - 2030 (USD Billion)
Figure 19 Global research antibodies market, for polyclonal antibodies, 2018 - 2030 (USD Billion)
Figure 20 Global research antibodies market: Technology movement analysis
Figure 21 Global research antibodies market, for immunohistochemistry, 2018 - 2030 (USD Billion)
Figure 22 Global research antibodies market, for immunofluorescence, 2018 - 2030 (USD Billion)
Figure 23 Global research antibodies market, for western blotting, 2018 - 2030 (USD Billion)
Figure 24 Global research antibodies market, for flow cytometry, 2018 - 2030 (USD Billion)
Figure 25 Global research antibodies market: immunoprecipitation, movement analysis
Figure 26 Global research antibodies market, for ELISA, 2018 - 2030 (USD Billion)
Figure 27 Global research antibodies market, for other technologies, 2018 - 2030 (USD Billion)
Figure 28 Global research antibodies market: Source movement analysis
Figure 29 Global research antibodies market, for mouse, 2018 - 2030 (USD Billion)
Figure 30 Global research antibodies market, for rabbit, 2018 - 2030 (USD Billion)
Figure 31 Global research antibodies market, for goat, 2018 - 2030 (USD Billion)
Figure 32 Global research antibodies market, for other sources, 2018 - 2030 (USD Billion)
Figure 33 Global research antibodies market: Application movement analysis
Figure 34 Global research antibodies market, for infectious diseases, 2018 - 2030 (USD Billion)
Figure 35 Global research antibodies market, for immunology, 2018 - 2030 (USD Billion)
Figure 36 Global research antibodies market, for oncology, 2018 - 2030 (USD Billion)
Figure 37 Global research antibodies market, for stem cells, 2018 - 2030 (USD Billion)
Figure 38 Global research antibodies market, for neurobiology, 2018 - 2030 (USD Billion)
Figure 39 Global research antibodies market, for other applications, 2018 - 2030 (USD Billion)
Figure 40 Global research antibodies market: End-use movement analysis
Figure 41 Global research antibodies market, for academic & research institutes, 2018 - 2030 (USD Billion)
Figure 42 Global research antibodies market, for contract research organizations, 2018 - 2030 (USD Billion)
Figure 43 Global research antibodies market, for pharmaceutical & biotechnology companies, 2018 - 2030 (USD Billion)
Figure 44 Regional marketplace: key takeaways
Figure 45 Regional outlook, 2023 & 2030
Figure 46 Global research antibodies market: region movement analysis
Figure 47 North America research antibodies market, 2018 - 2030 (USD Billion)
Figure 48 U.S. research antibodies market, 2018 - 2030 (USD Billion)
Figure 49 Canada research antibodies market, 2018 - 2030 (USD Billion)
Figure 50 Europe research antibodies market, 2018 - 2030 (USD Billion)
Figure 51 Germany research antibodies market, 2018 - 2030 (USD Billion)
Figure 52 UK research antibodies market, 2018 - 2030 (USD Billion)
Figure 53 France research antibodies market, 2018 - 2030 (USD Billion)
Figure 54 Italy research antibodies market, 2018 - 2030 (USD Billion)
Figure 55 Spain research antibodies market, 2018 - 2030 (USD Billion)
Figure 56 Denmark research antibodies market, 2018 - 2030 (USD Billion)
Figure 57 Sweden research antibodies market, 2018 - 2030 (USD Billion)
Figure 58 Norway research antibodies market, 2018 - 2030 (USD Billion)
Figure 59 Asia Pacific research antibodies market, 2018 - 2030 (USD Billion)
Figure 60 Japan research antibodies market, 2018 - 2030 (USD Billion)
Figure 61 China research antibodies market, 2018 - 2030 (USD Billion)
Figure 62 India research antibodies market, 2018 - 2030 (USD Billion)
Figure 63 Australia research antibodies market, 2018 - 2030 (USD Billion)
Figure 64 Thailand research antibodies market, 2018 - 2030 (USD Billion)
Figure 65 South Korea research antibodies market, 2018 - 2030 (USD Billion)
Figure 66 Singapore research antibodies market, 2018 - 2030 (USD Billion)
Figure 67 Latin America research antibodies market, 2018 - 2030 (USD Billion)
Figure 68 Brazil research antibodies market, 2018 - 2030 (USD Billion)
Figure 69 Mexico research antibodies market, 2018 - 2030 (USD Billion)
Figure 70 Argentina research antibodies market, 2018 - 2030 (USD Billion)
Figure 71 MEA research antibodies market, 2018 - 2030 (USD Billion)
Figure 72 South Africa research antibodies market, 2018 - 2030 (USD Billion)
Figure 73 Saudi Arabia research antibodies market, 2018 - 2030 (USD Billion)
Figure 74 UAE research antibodies market, 2018 - 2030 (USD Billion)
Figure 75 Kuwait research antibodies market, 2018 - 2030 (USD Billion)
Market Segmentation
There has been a rise in R&D activities by leading biopharmaceutical, pharmaceutical, and biotechnology manufacturers to develop innovative antibodies such as in monoclonal antibodies. Increasing focus on R&D and development of new products is expected to propel long-term growth in the business. For instance, in 2016, Novartis invested USD 9 billion in research and development, whereas Pfizer invested USD 7.9 billion in the same year for the development of novel products and technologies. According to the International Trade Administration (ITA), U.S. Department of Commerce, the U.S. biopharmaceutical sector accounted for 17% of domestic research and development and USD 1.2 trillion in economic output in the year 2014.
Research antibodies are complex and sophisticated structures that are being increasingly used in research & academic institutions as well as major pharmaceutical & biotechnology companies, thus attracting investments in R&D for developing advanced generation of antibodies. The high prevalence of cancer and other chronic diseases has led to an increase in the demand for R&D in research antibodies. Increasing awareness among individuals about the diagnostic properties of research antibodies has led to an increase in their demand. Research antibodies such as monoclonal antibodies are being increasingly adopted globally.
Government initiatives promoting cell therapeutics research is widening market growth prospects. Due to extensive research activities, the number of diseases treated with the help of stem cells increased to 82 from 27 in 2005. CIRM’s funding of USD 271 million for stem cell research created 12 research spaces in California, which further brought in approximately USD 543 million funding for stem cell research. National Institutes of Health invested approximately USD 1,429 million for stem cell research in 2015. Increase in number of collaborations of research institutes with various public and private entities to promote cell research has provided significant boost to the market.
For instance, the federal government of Canada announced USD 20 million in funding to the Centre for Commercialization of Regenerative Medicine, a cell regeneration research facility, to improve cell therapy manufacturing challenges. Growing number of proposed guidelines and recommendations for public and private laboratories to ensure high quality standards and facilitate generation of accurate results in cell research are likely to improve adoption of cell counters in the near future. For instance, in May 2016, the International Society for Stem Cell Research (ISSCR) updated guidelines for development of cell-based therapy and stem cell research.
High growth in pharmaceutical and biopharmaceutical industries has been boosting market expansion. A major factor restraining market growth is the presence of stringent guidelines during development and research antibodies to ensure high quality products. Incorporation of cGMP and aseptic processing in all FDA regulated laboratories has made approval of research antibodies products relatively complex. In order to curb contamination, products are validated on various parameters, thereby lengthening the approval process. Stringent regulations issued by animal welfare organizations with respect to derivation process of antibodies from animal sources may also hamper market growth.
This section will provide insights into the contents included in this research antibodies market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.
Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
Company overview
Financial performance
Product benchmarking
Latest strategic developments
Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance
A three-pronged approach was followed for deducing the research antibodies market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:
Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for research antibodies market to gather the most reliable and current information possible.
Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of research antibodies market data depending on the type of information we’re trying to uncover in our research.
Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.
Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.
Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.
Qualitative Functional Deployment (QFD) Modelling for market share assessment.
Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.
Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.
Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.
This step also entails the finalization of the report scope and data representation pattern.
Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.
The research antibodies market was categorized into seven segments, namely product (Primary Antibodies, Secondary Antibodies), type (Monoclonal Antibodies, Polyclonal Antibodies), technology (Immunohistochemistry, Immunofluorescence, Western Blotting, Flow Cytometry, Immunoprecipitation, ELISA), source (Mouse, Rabbit, Goat), application (Infectious Diseases, Immunology, Oncology, Stem Cells, Neurobiology), end-use (Academic & Research Institutes, Contract Research Organizations, Pharmaceutical & Biotechnology Companies), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).
The research antibodies market was segmented into product, type, technology, source, application, end-use, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:
Demand estimation of each product across countries/regions summed up to from the total market.
Variable analysis for demand forecast.
Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.
Primary interviews for data revalidation and insight collection.
Used extensively for new product forecasting or analyzing penetration levels.
Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.
Primary interviews and vendor-based primary research for variable impact analysis.
The research antibodies market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-four countries, namely, the U.S.; Canada; the UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; India; Japan; Australia; Thailand; South Korea; Singapore; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait.
All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.
The research antibodies market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:
Abcam plc is a company specializing in the production and marketing of protein research tools. This company is useful in the field of diagnostics, drug discovery, and other research work. Its product segment includes antibodies, research-grade antibodies, IVD antibodies, antagonists, activators, and inhibitors, and proteins & peptides. Abcam serves more than 130 countries globally and is headquartered in the UK, with 11 additional centers in the U.S., Asia, and other parts of UK.
Bio-Rad Laboratories Inc. develops and manufactures systems and products used in separating complex biological and chemical materials, as well as to analyze, identify, and purify their respective components. In clinical diagnostics segment, the company designs, manufactures, supports, and sell informatics systems, test systems, quality controls, and test kits. These products serve clinical laboratories in the global market. The company’s diagnostic products consist of a range of technologies and aims at delivering high value clinical information. Similarly, life sciences segment aims at creating and discovering tools, required in biological processes. The company develops, manufactures and markets apparatus, reagents, and laboratory instruments, which are used exclusively in the process of biopharmaceutical production, research techniques, and food testing regimes. Key end-users of Bio-Rad products include hospitals, research institutions, laboratories, biotechnology companies, and pharmaceutical firms.
BD (Becton Dickinson & Company) is an American medical technology firm that develops, produces, and sells medical devices, laboratory equipment, and medical supplies. The medical segment provides catheters, needle free connectors, extension sets, fluids, drug transfer diseases, hazardous drug detection, anesthesia needles, disposal systems, dedicated disposables, infusion pumps, automated medication dispensing, products for diabetes care. The Life Science segment provides specimen & blood collection systems and products, automated blood and tuberculosis culturing, microorganism detection, molecular testing, rapid diagnostic assays, monitoring reagents and analyzers. The company operates in more than 50 countries across the globe.
Merck Millipore is a provider of a wide range of pharmaceutical and chemical products catering various industries. This company operates through three business sectors i.e., healthcare, life science and performance materials. The company offers life science products and services for drug discovery and development along with research and laboratory applications. It also provides prescription medicines for the treatment of multiple sclerosis, colorectal cancer, diabetes, cardiovascular diseases, infertility and others. The company also provides over the counter medicines, probiotic supplements and various other products for women’s health and nutrition. It has strategic collaborations with companies such as Pfizer, Intrexon Corporation, and Bristol-Myers Squibb. The company operates in over 66 countries globally.
Lonza caters to pharmaceutical, consumer health, biotech, and specialty ingredients industries. Lonza develops preventive and curative medicines, nutritional ingredients, and personal care products. The company operates through two business segments—Pharma & Biotech and Specialty Ingredients. The former segment includes chemical and biologics division along with bioscience solutions and capsule delivery solutions business units. The Specialty Ingredients segment includes consumer health division, consumer & resources protection division, and water care business unit. The company supplies its products to about 30 countries across the globe and has approximately 53 manufacturing and R&D facilities.
Thermo Fisher Scientific Inc. is a manufacturer and provider of laboratory reagents and equipment, analytical instruments, software, reagents, instrument systems, chemicals, consumables and diagnostic products. The company services and supplies through premier brands such as Thermo Scientific, Fisher Scientific, Applied Biosystems, and Invitrogen. The company’s life science solutions segment offers reagents, consumables, and instruments for biological and medical research, discovery and production of new drugs and vaccines and also diagnosis of diseases catering to pharmaceutical, biotechnology, agricultural, clinical and academic as well as government markets. Its Analytical Instrument segment provides equipment’s and instruments along with consumables and services which have various applications on the production line, laboratory and on the field. Its Solutions segment provides instruments and reagents & consumables that are used in diagnosis of diseases, medical & biological research as well as in the discovery of new drugs and vaccines.
Cell Signaling Technology is a private company specializing in the development of antibody products for clinical diagnostics and medical research markets. Its products include primary antibodies, antibody sampler, secondary antibodies, antibody conjugates, ELISA kits, proteomic kits, and many others. It also provides custom antibody conjugation and proteomic services. This company has its offices located in Japan, China, and the Netherlands.
F. Hoffmann-La Roche Ltd. is a multinational healthcare company operating under two segments: Diagnostics and Pharmaceuticals. The company has expertise in drugs for cancer and transplantation, virology, metabolism, inflammation, clinical chemistry, CNS, immunology, blood screening, urinalysis, infectious diseases, microbiology and genetics. The company is also into research, development, and production of molecular diagnostic reagents, test kits and test systems and provides automated instruments, software, IT solutions and consumables which are extensively used in in-vitro research and diagnostics. It is presently operating as a subsidiary of Roche Holding AG in over 100 countries.
Agilent Technologies, Inc. is involved in developing, manufacturing, and research that provides application focused solutions to the diagnostics, life sciences, and applied chemical markets globally. It operates through three segments: Diagnostics, Agilent CrossLab, Applied science market, Life sciences market and Genomics. The company serves routine and clinical diagnostics markets and analytical laboratories with varied technology platforms such as bio reagents, automation, FISH probes, liquid chromatography, informatics, immunohistochemistry, microarrays, mass spectrometry, vacuum technologies and others.
PerkinElmer, Inc., is an American company that offers products, solutions, and services to the life sciences, diagnostics, and applied services market. The company majorly operates in two segments – diagnostics & discovery, and analytical solutions. The analytical solutions segment offer product such as reagents, detection and imaging technologies and informatics that help scientists to enhance research in life sciences research & laboratory services market. It also provides analytical solutions, technologies, and services for food, environmental and industrial markets. The diagnostics segment offers instruments, software products, reagents that is used for early detection of genetic disorders and infectious disease testing. Products of this segment can also be used for screening and testing genetic abnormalities, diseases and disorders that include hypothyroidism, Down syndrome, infertility, and other metabolic diseases. The company serves biotechnological and pharmaceutical companies, clinical research institutions, private health organizations, doctors, public health authorities, and government agencies.
Supply Side Estimates
Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.
Segment revenue determination via variable analysis and penetration modeling.
Competitive benchmarking to identify market leaders and their collective revenue shares.
Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.
Demand side estimates
Identifying parent markets and ancillary markets
Segment penetration analysis to obtain pertinent
revenue/volume
Heuristic forecasting with the help of subject matter experts
Forecasting via variable analysis
Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.
Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.
Understanding market estimates and forecasts (with the base year as 2023, historic information from 2018 to 2023, and forecast from 2024 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.
The report provides market value for the base year 2023 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.
The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.
We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.
All market estimates and forecasts have been validated through primary interviews with the key industry participants.
Inflation has not been accounted for to estimate and forecast the market.
Numbers may not add up due to rounding off.
Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).
Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).
Latin America includes Central American countries and the South American continent
Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.
GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.
We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:
Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.
Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.
The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."